Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved ...

CNM-Au8 30mg treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels at 76 weeks relative to placebo (18 months from randomization, p=0.023)60% decreased risk of long-term all-cause mortality (>18

Related Keywords

Salt Lake City ,Utah ,United States ,Massachusetts ,Maryland ,Benjamin Greenberg ,Jamesd Berry ,Seanm Healey ,Motor Neuron Disorder Division ,Linkedin ,Nasdaq ,Neurology Department ,Twitter ,Securities Exchange ,Clene Inc ,Clene Nanomedicine Inc ,Neurological Clinical Research Institute At Massachusetts ,Analysis Validates Association Of Nf ,Term Plasma Nfl Biomarker Findings ,Trial Open Label Extension ,Mixed Model ,Repeat Measures ,Least Squared Means ,Natural Log ,Associate Professor ,Neurological Clinical Research Institute ,Massachusetts General Hospital ,Term Survival Improvement ,Chair Neurology Department ,Mass General Hospital ,Julianne Dorn Professor ,Neurology Harvard Medical School ,Principal Investigator ,Analysis Validates Association ,Clinical Morbidity Outcomes ,High Risk ,Clene Nanomedicine ,Open Label Extension ,Combined Assessment ,Securities Exchange Act ,Securities Act ,Annual Report ,Quarterly Reports ,Region ,